Your World of Legal Intelligence
 United Kingdom | +44 (0) 20 7284 8080

NightWare awarded US FDA breakthrough status for NightWare for Post-Traumatic Stress Disorder (PTSD).

Document Cited in Related
Vincent

Global Banking News-May 22, 2019-NightWare awarded US FDA breakthrough status for NightWare for Post-Traumatic Stress Disorder (PTSD)

(C)2019 ENPublishing - http://www.enpublishing.co.uk

Healthcare startup NightWare, Inc reported on Tuesday the receipt of the US Food and Drug Administration (FDA) breakthrough status designation for its lead product NightWare that measures and treats nightmares in people with Post-Traumatic Stress Disorder (PTSD).

Following the US FDA breakthrough status designation, the company said it can expedite its clinical trials and review cycles, shortening the timeline to broad clinical availability of its groundbreaking technology.

Currently, the company is enrolling patients in two Randomized Clinical Trials (RCTs), one of which is being conducted at VA hospitals in Minneapolis and St Cloud, Minnesota. It is enrolling a virtual RCT trial that is much broader in geographic scope.

The company added that the NightWare is a smart watch application that runs on the Apple...

To continue reading

Request your trial
COPYRIGHT Normans Media Ltd.

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT